Novavax (NVAX) Capital Leases (2012 - 2026)

Novavax's Capital Leases history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Capital Leases fell 96.41% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 96.41% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 96.11% from the prior year.
• Capital Leases slipped to $1.9 million in Q1 2026 per NVAX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Capital Leases topped out at $55.9 million in Q4 2023 and bottomed at $1.9 million in Q1 2026.
• The 5-year median for Capital Leases is $52.4 million (2025), against an average of $37.5 million.
• Across the five-year window, Capital Leases soared 79.02% in 2023 and sank 96.41% in 2026, its largest moves.
• Year by year, Capital Leases stood at $31.2 million in 2022, then surged by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024, then tumbled by 96.11% to $2.1 million in 2025, then slipped by 8.8% to $1.9 million in 2026.
• Per Business Quant, the three latest NVAX Capital Leases figures stand at $1.9 million (Q1 2026), $2.1 million (Q4 2025), and $2.3 million (Q3 2025).